Trial Profile
An Individualized Anti-Cancer Vaccine (AlloVaxTM) Study in Patients With Refractory Hepatocellular Carcinoma (HCC)
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs T-cell vaccine AlloVax (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- Sponsors Immunovative Therapies
- 01 Apr 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 03 Dec 2013 New trial record